New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:02 EDTGHDXGenomic Health announces data reinforcing robustness of Oncotype DX
Genomic Health presented positive results reinforcing the robustness of the Oncotype DX prostate cancer test's development as a predictor of prostate cancer aggressiveness. A sub-analysis of a large Oncotype DX Genomic Prostate Score, or GPS, development study suggests that GPS predicts time to clinical progression regardless of the treatment received following surgery. This exploratory analysis from one of the original development studies looked at a subset of 185 prostate cancer patients who experienced biochemical recurrence after surgery. These patients were analyzed in three subgroups based on treatment received at time of biochemical recurrence: men who did not receive additional treatment, men who received hormonal therapy and men who received radiation therapy. Results showed that the Oncotype DX Genomic Prostate Score was predictive of clinical recurrence for all patients, regardless of the type of treatment patients received. For each therapy subgroup, different biological pathways within the GPS were most highly associated with patient outcome.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:05 EDTGHDXGenomic Health announces positive results for validation study of Oncotype DX
Genomic Health announced strongly positive results from an additional independent clinical validation study of the Oncotype DX prostate cancer test. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen following surgery. In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer. Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men. The Oncotype DX GPS was also significantly predictive of metastatic prostate cancer recurrence, a notable finding given the likelihood of metastases in patients with low- and intermediate-risk prostate cancer is so small.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use